OABI stock news · OmniAb, Inc.
Get alerts for OABI
Follow OmniAb, Inc. (OABI) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for OABIOmniAb shared its third-quarter results, showing revenue growth and a big deal with Eli Lilly.
Good for OABIOmniAb reported higher third-quarter sales, raised its 2026 sales outlook, and signed a Lilly licensing deal. These changes point to a stronger business outlook, though future payments depend on program progress.
12 health care stocks are changing in price before the market opens, with NRX Pharmaceuticals going up and Acumen Pharmaceuticals dropping.
NeutralOmniAb shares fell about 16%, and the report says its Q3 results came out that day. It gives no results or new company details, so this story does not change the business outlook.
Gold increases by 1%; August sees a rise in the NY Empire State Manufacturing Index.
NeutralThe article highlights significant stock movements driven by company-specific news, including OmniAb's collaboration with Eli Lilly and positive results from argenx's clinical trial, indicating strong investor interest and potential growth in these biotech firms.
OmniAb's shares soar following partnership agreement with Eli Lilly.
NeutralOmniAb's stock surged following the announcement of a collaboration with Eli Lilly, which includes up to $370 million in milestone payments and an improved cash outlook for 2026. This partnership is expected to leverage OmniAb's ion channel discovery capabilities, indicating strong future growth potential.